+28.2%
MRNA vs ACGL
+30.4%
-2.2%
-86.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | ACGL | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.4% | +0.4% | -3.8% | -3.3% |
| 7D | -10.1% | -2.1% | -8.0% | -10.1% |
| 30D | +126.7% | -2.2% | +128.9% | +126.5% |
| 3M | +184.1% | +6.3% | +177.8% | +183.1% |
| 6M | +143.3% | +0.5% | +142.8% | +142.8% |
| YTD | +359.9% | +0.2% | +359.6% | +358.0% |
| 1Y | +454.2% | +7.3% | +446.9% | +447.3% |
| All | +28.2% | +30.4% | -2.2% | +33.1% |
Cumulative growth
Daily Returns
Daily percentage return beside ACGL.
Daily Out/Under-Performance
Portfolio return minus ACGL return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × ACGL return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded ACGL wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling